Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Disitamab Vedotin for High-risk NMIBC
NCT06378242Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Jun 2024
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Non-muscle-invasive bladder cancer (NMIBC), sponsored by RemeGen. Started Jun 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06378242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378242.